PROTAGONIST THERAPEUTICS INC(NASDAQ:PTGX) stock News

PTGX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Chartmill - Mentions: JNJ AMZN AAPL NVDA ...

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears

14 days ago - By: Chartmill - Mentions: SLE NVX VG XBIO ...

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

14 hours ago - By: The Motley Fool - Mentions: GTLS BXS PIPR INDB ...

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

14 hours ago - By: The Motley Fool - Mentions: SKWD INDB KTOS BXS ...

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million

10 days ago - By: Stocktwits - Mentions: JNJ LEGN

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

10 days ago - By: Stocktwits - Mentions: JNJ

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

11 days ago - By: Zacks Investment Research - Mentions: JNJ PFE

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

14 days ago - By: Chartmill - Mentions: NVX XBIO APM ANVS ...

Which stocks are experiencing notable movement on Friday?

14 days ago - By: Bloomberg - Mentions: JNJ

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ

16 days ago - By: Benzinga

5 Analysts Assess Protagonist Therapeutics: What You Need To Know

17 days ago - By: ACCESS Newswire

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

a month ago - By: Benzinga

Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews

a month ago - By: ACCESS Newswire

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

a month ago - By: ACCESS Newswire

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

a month ago - By: ACCESS Newswire

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

2 months ago - By: ACCESS Newswire

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

2 months ago - By: ACCESS Newswire

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

3 months ago - By: Zacks Investment Research - Mentions: DVAX

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

3 months ago - By: ACCESS Newswire

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

3 months ago - By: ACCESS Newswire

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

4 months ago - By: Investor's Business Daily - Mentions: LLY NVO AZN PFE ...

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

4 months ago - By: ACCESS Newswire

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

4 months ago - By: ACCESS Newswire

PROTAGONIST THERAPEUTICS INC (PTGX) Stock News

PTGX Latest News, Press Relases and Analysis

Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears

Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.

Moody Aldrich Dumps Entire Stake in Chart Industries Worth $5.8 Million

Moody Aldrich Fully Exits 136K SKWD Shares Worth $7.8 Million

Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print

BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In

Protagonist Therapeutics Stock Gains 30% as J&J Reportedly Eyes Deal

Which stocks are experiencing notable movement on Friday?

Johnson & Johnson in Talks to Buy Protagonist Therapeutics: WSJ

5 Analysts Assess Protagonist Therapeutics: What You Need To Know

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill

Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews

Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress

Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025

Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency

Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025

Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera

Protagonist Therapeutics (PTGX) Reports Q2 Loss, Lags Revenue Estimates

Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Protagonist Announces Submission of NDA for First Icotrokinra U.S. FDA Approval Aiming to Revolutionize Treatment Paradigm for Adults and Adolescents with Plaque Psoriasis

Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?

Protagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for Obesity

Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate